^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | pomalidomide (TNFα inhibitor, IL-6 inhibitor, NK cell stimulant, IL-10 stimulant, IL-1β inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
08/05/2013
Excerpt:
Imnovid in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy...Imnovid in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide.
Secondary therapy:
; bortezomib
Source:
Excerpt:
POMALYST is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Source:
Excerpt:
POMALYST is a thalidomide analogue indicated, for the treatment of adult patients:...in combination with dexamethasone, for patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy
Source:
Excerpt:
…the NCCN Panel has included pomalidomide/cyclophosphamide/dexamethasone as a treatment option for patients with relapsed/refractory MM who have received at least one prior therapy.
Secondary therapy:
cyclophosphamide
Source:
Excerpt:
…the NCCN Panel has included pomalidomide plus dexamethasone as a therapeutic option in patients…
Source:
Excerpt:
The NCCN panel has included this regimen pomalidomide/carfilzomib/dexamethasone as a therapeutic option in patients who have received at least two prior therapies...
Secondary therapy:
carfilzomib
Source:
Title:
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse
Published date:
09/07/2020
Excerpt:
OPTIMISMM is an international, randomized, open-label, controlled, phase 3 clinical trial (NCT01734928)….In all patients treated with PVd at first relapse, PFS and ORR were significantly improved vs in those treated with Vd (PFS: median, 20.73 vs 11.63 months; HR, 0.54 [95% CI, 0.36–0.82]; P = 0.0027...ORR: 90.1 vs 54.8%; odds ratio [OR], 7.50 [95% CI, 3.64–15.46]; P < 0.001; Supplemental Table 2).
Secondary therapy:
bortezomib
DOI:
10.1038/s41375-020-01021-3
Trial ID:
Source:
Title:
A National, Multicenter, Non-Interventional Study of Pomalidomide in Relapsed/Refractory Multiple Myeloma: Updated Results from the Miroir Study
Published date:
11/01/2018
Excerpt:
A total of 1581 patients were included in this analysis (median follow-up, 19.1 months)...The results of this interim analysis of the real-world MIROIR study confirm the efficacy of POM reported in clinical trials and underscore its role as a treatment in RRMM. Median PFS was numerically longer in patients who had received only 1 to 2 prior lines of therapy, supporting earlier initiation of POM.
Trial ID:
